Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 296

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 296
---
 Business Combination on antitrust grounds will not be made or, if such a challenge is made, that it would not be successful. APx and the Company are not aware of any other regulatory approvals in the United States and Cayman Islands or elsewhere required for the consummation of the Business Combination. Litigation Relating to the Business Combination There have been no proceedings brought against APx in relation to the Business Combination or the Business Combination Agreement. Listing of Company Shares Approval of the listing on Nasdaq of the Company Shares to be issued in the Business Combination, subject to official notice of issuance, is a condition to each party’s obligation to complete the Business Combination.

137 Accounting Treatment of the Business Combination OmnigenicsAI will account for the Business Combination as a capital reorganization in accordance with IFRS as issued by the IASB. Under this method of accounting, APx will be treated as the “acquired” company for financial reporting purposes and OmnigenicsAI will be the accounting “acquirer.” This determination was primarily based on the assumptions that OmnigenicsAI’s shareholders will hold a majority of the voting power of the Combined Company, OmnigenicsAI’s operations will substantially comprise the ongoing operations of the Combined Company, OmnigenicsAI’s designees are expected to comprise a majority of the governing body of the Combined Company, and OmnigenicsAI’s senior management will comprise the senior management of the Combined Company. APx does not meet the definition of a “business” pursuant to IFRS3, Business Combinations, and thus, for accounting purposes, OmnigenicsAI will account for the Business Combination as a capital reorganization. The net assets of APx will be stated at historical cost, with no goodwill or other intangible assets recorded. The Business Combination will be accounted for within the scope of IFRS 2. As a result, any excess of fair value of the Company Shares issued over the fair value of APx’s identifiable net assets acquired, represent compensation for the service in respect of a stock exchange listing for the Company Shares and is expensed upon consummation. 138 The Business Combination Agreement This section of the proxy statement / prospectus describes the material provisions of the Business Combination Agreement, but does not purport to describe all of the terms of the Business Combination Agreement. This summary is qualified in its entirety by reference to the Business Combination Agreement, a copy of which is attached as Annex A hereto. Certain figures included in this section have been rounded for ease of presentation and, as